12
Participants
Start Date
October 30, 2018
Primary Completion Date
March 30, 2022
Study Completion Date
October 3, 2023
Laboratory Biomarker Analysis
Correlative studies
NT-I7
Given IM
Placebo
Given IM
Memorial Sloan-Kettering Cancer Center, New York
Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh
Abrams Cancer Center of the University of Pennsylvania, Philadelphia
Johns Hopkins Oncology Center, Baltimore
Cleveland Clinic Taussig Cancer Center, Cleveland
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit
Washington University, St Louis
UAB Comprehensive Cancer Center, Birmingham
Dana Farber Cancer Institute, Boston
Wake Forest University Comprehensive Cancer Center, Winston-Salem
Collaborators (1)
National Cancer Institute (NCI)
NIH
NeoImmuneTech
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER